Differential effects of L-dopa and apomorphine on glucagon secretion in man: evidence against central dopaminergic stimulation of glucagon

The Journal of Clinical Endocrinology and Metabolism
M LorenziP H Forsham


In 6 normal subjects, L-dopa (500 mg PO) and apomorphine (0.6 mg sc) increased circulating growth hormone and suppressed prolactin levels in a parallel and quantitatively similar fashion, but only L-dopa induced a rise in plasma glucagon, glucose, and insulin levels. The failure of apomorphine to affect glucagon secretion, despite a substantial effect on growth hormone and prolactin, was also observed in insulin-dependent diabetics known to exhibit A-cell hyperresponsiveness to various stimuli. In view of the highly dissimilar molecular and pharmacologic characteristics of L-dopa and apomorphine, these data do not exclude a local dopaminergic effect of L-dopa at the pancreatic level, but strongly militate against a central dopaminergic pathway for glucagon stimulation.


Oct 1, 1984·Acta diabetologica latina·P MatsumotoJ C Dunbar
Oct 26, 1979·European Journal of Pharmacology·M J Schmidt
Aug 1, 1979·European Journal of Pharmacology·H MizoguchiJ P Green
Feb 1, 1979·The Journal of Clinical Investigation·M LorenziP H Forsham
Oct 1, 1981·Journal of Endocrinological Investigation·G A ZampaL F Agnati
Feb 17, 2021·Translational Psychiatry·Despoina AslanoglouZachary Freyberg

Related Concepts

Blood Glucose
Diabetes, Autoimmune
Dopamine Receptor
Recombinant Growth Hormone

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.